Two new antiviral pills have been shown to be safe and effective against COVID in clinical trials, according to recent press releases. The drugs, molnupiravir, developed by Merck and Ridgeback Biotherapeutics, and Paxlovid, developed by Pfizer both seem to significantly reduce hospitalization in people with early COVID. Some researchers are quietly hopeful that these new weapons in the anti-COVID arsenal could have a big impact, in particular in parts of the world where vaccines are still not widely available, but there are a number of caveats. In this episode of Coronapod, we open the pill boxes and pick through the contents — asking how the drugs work, what side effects we might see, and how, if at all, they might change the course of the pandemic.
News: COVID antiviral pills: what scientists still want to know
Never miss an episode: Subscribe to the Nature Podcast on Apple Podcasts, Google Podcasts, Spotify or your favourite podcast app. Head here for the Nature Podcast RSS feed.
The race for antiviral drugs to beat COVID — and the next pandemic
Some antibodies can dampen antiviral defences in people with severe COVID
Read the paper: Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells
